GSK’s Malaria Vaccine Loses Efficacy Over Several Years Among Kenyan Children, Study Shows; Researchers To Test 4 Dose Regimen

Agence France-Presse: Malaria vaccine loses effectiveness over several years: study
“An experimental vaccine against malaria known as Mosquirix — or RTS,S — weakens over time and is only about four percent effective over a seven-year span, researchers said Wednesday…” (6/29).

The Guardian: Malaria vaccine study raises questions about effectiveness and dosage
“…In spite of the results of the trial in Kilifi, Kenya, which was published in the New England Journal of Medicine, those behind the development of the vaccine said it must still be rolled out in pilot programs to thousands of children in Africa by the World Health Organization as planned. The children will be given four doses rather than three…” (Boseley, 6/29).

Reuters: Limited protection of GSK’s malaria vaccine dwindles in 7 years
“…[R]esearchers said the decline in its efficacy over time is fastest in children living in areas with higher than average rates of malaria. This raises questions about whether Mosquirix can play a meaningful role in fighting malaria, they said, and suggests a four-dose schedule would be needed if it were used…” (Kelland, 6/29).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.